![David Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 439 061 $ al 30/06/2026
Currently, David V.
Smith serves as Independent Director at Codexis, Inc. since 2016, Director at Neurelis, Inc. since 2021, Director at Acepodia Biotechnologies, Ltd. since 2022, and Strategic Advisor at Monterey Innovation Acquisition Corp.
Formerly, the roles include Director at Perlegen Sciences, Inc. from 2006 to 2009, Independent Director at OncoGenex Pharmaceuticals, Inc., Director at Acepodia, Inc. (United States) from 2022 to 2023, Independent Director at IO Biotech, Inc. from 2022 to 2026, CFO, Principal Accounting Officer, VP & Controller at Chiron Corp.
from 1999 to 2006, Principal at Genentech, Inc. from 1988 to 1997, Principal at International Business Machines Corp., Principal at Syntex Corp., Chief Financial Officer & Vice President-Finance at Anergen, Inc. from 1997 to 1999, Chief Financial Officer & Executive Vice President at Thoratec Corp.
from 2006 to 2011, Chief Financial Officer & Executive Vice President at Five Prime Therapeutics, Inc. from 2018 to 2021, and Chief Operating Officer at IntegenX, Inc. from 2012 to 2018.
Education includes an MBA from Golden Gate University conferred in 1987 and an undergraduate degree from Willamette University conferred in 1981.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CODEXIS, INC. 0,21 % | 17/06/2026 | 194.275 ( 0,21 % ) | 439 062 $ | 30/06/2026 |
IO BIOTECH, INC. -.--% | 05/06/2025 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CODEXIS, INC. | Director/Miembro de la Junta | 01/03/2016 |
| MONTEREY INNOVATION ACQUISITION CORP. | Corporate Officer/Principal | - |
Acepodia Biotechnologies, Ltd.
 Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Develops novel, targeted, allogeneic cell therapies to treat cancers | Director/Miembro de la Junta | 06/01/2022 |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes product candidates for the treatment of central nervous system disorders | Director/Miembro de la Junta | 18/10/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| IO BIOTECH, INC. | Director/Miembro de la Junta | 31/03/2026 |
| FIVE PRIME THERAPEUTICS, INC. | Director Financiero/CFO | 16/04/2021 |
IntegenX, Inc.
 IntegenX, Inc. BiotechnologyHealth Technology Develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products | Director de Operaciones | 01/03/2018 |
| THORATEC CORPORATION | Director Financiero/CFO | 01/07/2011 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 17 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
International Business Machines Corp.
 International Business Machines Corp. Information Technology ServicesTechnology Services Provides software, IT consulting, cloud and infrastructure services | Technology Services |
Syntex Corp.
 Syntex Corp. Pharmaceuticals: MajorHealth Technology Pharmaceutical concern | Health Technology |
Anergen, Inc.
 Anergen, Inc. BiotechnologyHealth Technology Develops propriety therapeutics designed to interrupt the antigen process | Health Technology |
Thoratec Corp.
 Thoratec Corp. Medical SpecialtiesHealth Technology Manufactures and distributes circulatory support devices for heart failure patients | Health Technology |
Perlegen Sciences, Inc.
 Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Discovers and develops drugs | Retail Trade |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
IntegenX, Inc.
IntegenX, Inc. BiotechnologyHealth Technology Develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products | Health Technology |
Golden Gate University
 Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Willamette University
 Willamette University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Health Technology |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes product candidates for the treatment of central nervous system disorders | Health Technology |
Acepodia Biotechnologies, Ltd.
Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Develops novel, targeted, allogeneic cell therapies to treat cancers | Health Technology |
Monterey Innovation Acquisition Corp.
 Monterey Innovation Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
